AstraZeneca PLC (AZN)vsHumacyte Inc (HUMA)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
HUMA
Humacyte Inc
$0.84
+2.66%
HEALTHCARE · Cap: $178.93M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 2882088% more annual revenue ($58.74B vs $2.04M). AZN leads profitability with a 17.4% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
HUMA
Avoid14
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+58.3%
Fair Value
$2.42
Current Price
$0.84
$1.58 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 42.1x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : HUMA
HUMA has a balanced fundamental profile.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : HUMA
The primary concerns for HUMA are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
HUMA carries more volatility with a beta of 2.10 — expect wider price swings.
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 14/100), backed by strong 17.4% margins. HUMA offers better value entry with a 58.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Humacyte Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Humacyte Inc (HUMA) is a pioneering biotechnology company dedicated to revolutionizing vascular and regenerative medicine through the development of innovative human acellular vessels (HAVs). Focusing on urgent clinical needs for vascular reconstruction and chronic disease treatment, Humacyte provides off-the-shelf solutions designed to improve patient outcomes and lower healthcare costs. With its advanced technology platform, the company is poised to drive significant advancements in transplantation and tissue engineering, positioning itself as a leader in the evolving landscape of medical therapies.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?